Clinical Trial Finder

Inclusion Criteria:

• - Adult patients ≥ 18 years of age with one or more brain tumors planned for neurosurgical resection/biopsy.

• - Patients with concomitant leptomeningeal metastasis are eligible provided they have parenchymal brain neoplastic disease requiring resection/biopsy.

• - For all cohorts: no limit on prior CNS radiation or systemic therapyKPS ≥ 60.

• - Life expectancy >12 weeks.

• - Adequate treatment washout period from prior therapies to allow recovery from any prior treatment-related toxicities before enrollment in the judgment of the Investigator.

• - Adequate bone marrow, renal, hepatic, and coagulation parameters (obtained ≤7 days prior to the first day of study treatment): - Absolute neutrophil count (ANC) ≥1.0 × 10^3/μL (granulocyte-colony stimulating factor administration is not allowed within 1 week prior to C1D1) - Platelet count ≥10.0x10^4/μL.

Note: Participants requiring ongoing transfusions or growth factor support to maintain platelet count ≥10.0x10^4/μL are not eligible. (Platelet transfusion is not allowed within 1 week prior to C1D1)

• - Hemoglobin ≥ 7.0 g/dL (≥ 8 g/dL in gastric cancer / gastroesophageal cancer indications).

Note: Participants requiring ongoing transfusions or growth factor support to maintain hemoglobin ≥8.0 g/dL are not eligible (Red blood cell transfusion is not allowed within 1 week prior to C1D1)

• - Creatinine clearance ≥30 mL/min, as calculated using the Cockcroft-Gault equation.

• - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × upper limit of normal (ULN) (<5x ULN in participants with liver metastases) - Total bilirubin ≤1.5 × ULN) if no liver metastases or <3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline.

Exclusion Criteria:

• - Known allergy or hypersensitivity to study treatment or any of the study drug excipients.

For patients who are allergic to gadolinium-based agents may receive premedication as per institutional protocol or imaged without contrast at the discretion of the Principal Investigator; reactions will be managed per standard institutional protocol.

• - Multiple primary malignancies within 3 years, with the exception of: - adequately resected non-melanoma skin cancer.

• - carcinoma in situ of the cervix.

• - Smoldering pre-malignant or malignant conditions with minimal concern for CNS or extracranial progression during treatment such as CLL or MGUS based on the assessment of the treating provider.

• - curatively treated in-situ disease.

• - other solid tumors curatively treated.

- for patients with metastatic breast cancer: contralateral breast cancer

Arms

Experimental: DCOI naïve

Will receive the standard dose of sotorasib.

Active Comparator: Progressed on the DCOI

Will continue to receive the sotorasib dose they were previously receiving, according to their doctor's instruction.

Interventions

Drug: - Sotorasib

Enrolled patients will be administered DCOI at the FDA-recommended dose or continued on the DCOI at the discretion of the treating Oncologist per standard of care